Cancer Clinical Trials
To Participate in any of these clinical trials or for more information:
Call us at (808) 586-2979
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Study Number | Cancer Type | Study Details |
|---|---|---|
NRG-BN003 Local Principal Investigator: | Brain Keywords: Meningioma Subtype: | Official Title: Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Enrollment Status: Open: QMC, TCCOH Liliha Opt out: HPH Cancer Type: Brain ClinicalTrials.gov ID: NCT03180268 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A011801 Local Principal Investigator: | Breast Keywords: Adjuvant Subtype: Adjuvant | Official Title: The CompassHER2 Trial - (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib Enrollment Status: Open: HCC, KMCWC, Pali Momi, Straub, QMC Registration to the Quality of Life (A011801-H01) Substudy is Closed to Accrual as of 07/22/2024 Cancer Type: Breast ClinicalTrials.gov ID: NCT04457596 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
NRG-BR007 Local Principal Investigator: | Breast Keywords: Adjuvant Subtype: Adjuvant | Official Title: A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer Enrollment Status: Open: HCC, KMCWC, Straub, QMC XRT: TCCOH & QMC Cancer Type: Breast ClinicalTrials.gov ID: NCT04852887 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A012103 Local Principal Investigator: | Breast Keywords: Adjuvant Subtype: Adjuvant | Official Title: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy Enrollment Status: Open: HCC, KMCWC, Straub, QMC Cancer Type: Breast ClinicalTrials.gov ID: NCT05812807 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S2212 Local Principal Investigator: | Breast Keywords: Neoadjuvant Subtype: Adjuvant | Official Title: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study Enrollment Status: Open: HCC, Pali Momi, Straub Pending: QMC Cancer Type: Breast ClinicalTrials.gov ID: NCT05929768 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S1703 Local Principal Investigator: | Breast Keywords: Metastatic Subtype: Advanced/Metastatic 2nd line | Official Title: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer Enrollment Status: Open: HCC, KMCWC, QMC Cancer Type: Breast ClinicalTrials.gov ID: NCT03723928 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S2010 Local Principal Investigator: | Breast Keywords: Symptom Management Subtype: Symptom Management | Official Title: Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Vs Patient Education Alone to Improve Persistence With Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN) Enrollment Status: Open: HCC, KMCWC, Straub, Pali Momi, QMC Cancer Type: Breast ClinicalTrials.gov ID: NCT05568472 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
FUKUI-2019-1 Local Principal Investigator: | Breast Keywords: Exercise Subtype: Prevention (Non-interventional) | Official Title: A Pilot Study: The Effect of Longitudinal Exercise Programming in Breast Cancer Patients Enrollment Status: Open: RHOP Pending: HPH, QMC Cancer Type: Breast ClinicalTrials.gov ID: NCT04013568 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
NRG-CC008 Local Principal Investigator: | Breast Keywords: Surgical Procedure Subtype: Prevention (Non-interventional) | Official Title: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] Enrollment Status: Open: KMCWC Opt out: QMC Cancer Type: Breast ClinicalTrials.gov ID: NCT04251052 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ECOG-ACRIN-EA1151-TMIST Local Principal Investigator: | Breast Keywords: Screening Subtype: Screening (Non-interventional) | Official Title: Tomosynthesis Mammography Imaging Screening Trial Lead-in Enrollment Status: Open: QMC only Cancer Type: Breast ClinicalTrials.gov ID: NCT03233191 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
NRG-GI008 Local Principal Investigator: | Gastrointestinal Keywords: Adjuvant Subtype: Colorectal | Official Title: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) Enrollment Status: Open: HCC, Straub, Pali Momi, QMC Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT05174169 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A022004 Local Principal Investigator: | Gastrointestinal Keywords: Adjuvant Subtype: Colorectal | Official Title: Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer Enrollment Status: Open: HCC, Straub, Pali Momi Pending: QMC Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT05710406 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A022104 Local Principal Investigator: | Gastrointestinal Keywords: Neoadjuvant Subtype: Colorectal | Official Title: The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing The Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients With Locally Advanced Rectal Cancer Enrollment Status: Open: HCC, QMC Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT05610163 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
NRG-CC005 Local Principal Investigator: | Gastrointestinal Keywords: Prevention Subtype: Colorectal | Official Title: Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (FORTE) Enrollment Status: Open: QMC Opt out: HPH Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT05080673 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
CASSEL-2020-2 Local Principal Investigator: | Gastrointestinal Keywords: Supportive Care Subtype: Colorectal (Non-interventional) | Official Title: Improving Quality of Life for Colon Cancer Patients and Their Caregivers Enrollment Status: Open: HCC, Castle, Straub, Pali Momi, Kuakini, QMC Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT04713007 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ECOG-ACRIN-EA2174 Local Principal Investigator: | Gastrointestinal Keywords: Peri-operative Subtype: Esophageal/GEJ | Official Title: Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Enrollment Status: Temporarily Closed to Accrual as of 12/29/2022 Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT03604991 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A022102 Local Principal Investigator: | Gastrointestinal Keywords: Unresectable, metastatic Subtype: Esophageal/GEJ | Official Title: Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma Enrollment Status: Open: HCC, QMC Pending: HPH Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT05677490 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG S2303 Local Principal Investigator: | Gastrointestinal Keywords: Unresectable, 2L Subtype: Esophageal/Stomach | Official Title: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients With PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) Enrollment Status: Open: HCC Pending: QMC, HPH Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT06203600 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ACOBA-2017-2 Local Principal Investigator: | Gastrointestinal Keywords: No prior systemic treatment Subtype: Hepatocellular/Cholangiocarcinoma | Official Title: Phase II study of TSR-022 (COBOLIMAB) in combination with TSR-042 (DOSTARLIMAB) for the treatment of advanced hepatocellular carcinoma Enrollment Status: Open: HCC, QMC, OHSU Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT03680508 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
KWEE-2021-1 Local Principal Investigator: | Gastrointestinal Keywords: Pre-Treatment Subtype: Hepatocellular/Cholangiocarcinoma | Official Title: Clinical Trial of Biomarkers for Predicting Immunotherapy Response in Hepatocellular Carcinoma Enrollment Status: All sites may refer Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT04965454 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S2012 Local Principal Investigator: | Gastrointestinal Keywords: Neuroendocrine Carcinoma (NEC) Subtype: Neuroendocrine Carcinoma (NEC) | Official Title: Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC) Enrollment Status: Open: HCC, Straub, Pali Momi Pending: QMC Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT05058651 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A022106 Local Principal Investigator: | Gastrointestinal Keywords: Metastatic Subtype: Pancreatic | Official Title: Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM) Enrollment Status: Open: HCC, Pali Momi, Straub Pending: QMC Cancer Type: Gastrointestinal ClinicalTrials.gov ID: NCT06115499 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
NRG-GY019 Local Principal Investigator: | Gynecological Keywords: Adjuvant Subtype: Ovarian/Fallopian/Primary Peritoneal | Official Title: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Enrollment Status: Open: KMCWC, Pali Momi, QMC Cancer Type: Gynecological ClinicalTrials.gov ID: NCT04095364 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
NRG-GY026 Local Principal Investigator: | Gynecological Keywords: Chemo-naive / Non-recurrent Subtype: Ovarian/Fallopian/Primary Peritoneal | Official Title: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma Enrollment Status: Open: KMCWC, QMC Cancer Type: Gynecological ClinicalTrials.gov ID: NCT05256225 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
DB-1303-O-1001 Local Principal Investigator: | Gynecological Keywords: Advanced / Recurrent Subtype: Ovarian/Fallopian/Primary Peritoneal | Official Title: A Phase 1/2a, Multicenter, Open-Label, Non-Randomized First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors Enrollment Status: Open: KMCWC only Cancer Type: Gynecological ClinicalTrials.gov ID: NCT05150691 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ECOG-ACRIN-EAY191-N4 Local Principal Investigator: | Gynecological Keywords: ComboMATCH Subtype: Corpus Uteri/Ovary | Official Title: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients With Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial Enrollment Status: Open: KMCWC, QMC Cancer Type: Gynecological ClinicalTrials.gov ID: NCT05554328 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ECOG-ACRIN-EA3202 Local Principal Investigator: | Head & Neck Keywords: Advanced / Recurrent Subtype: Head & Neck | Official Title: A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers Enrollment Status: Open: HCC, QMC Opt out: HPH Cancer Type: Head & Neck ClinicalTrials.gov ID: NCT05063552 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S2101 Local Principal Investigator: | Head & Neck Keywords: Advanced Subtype: Head & Neck | Official Title: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study Enrollment Status: Temporarily Closed to Accrual as of 08/15/2024 Cancer Type: Head & Neck ClinicalTrials.gov ID: NCT05136196 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
WF-1805CD Local Principal Investigator: | Head & Neck Keywords: HN-STAR Subtype: Head & Neck Survivorship | Official Title: Implementation and Effectiveness Trial of HN-STAR Enrollment Status: Open: QMC only Cancer Type: Head & Neck ClinicalTrials.gov ID: NCT04208490 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ECOG-ACRIN-EA9181 Local Principal Investigator: | Hematologic Keywords: Newly Dx Subtype: Leukemias | Official Title: A Phase III Randomized Trial of Steroids + Tyrosine Kinase Inhibitor Induction With Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Enrollment Status: Open: HCC, Straub, Pali Momi Opt out: QMC Cancer Type: Hematologic ClinicalTrials.gov ID: NCT04530565 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A041501 Local Principal Investigator: | Hematologic Keywords: Precursor B-Cell ALL Subtype: Leukemias | Official Title: A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL Enrollment Status: Temporarily Closed to Accrual as of 05/24/2022 Cancer Type: Hematologic ClinicalTrials.gov ID: NCT03150693 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S1918 Local Principal Investigator: | Hematologic Keywords: Lymphoma (DLBCL) Subtype: Lymphomas | Official Title: A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Patients Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements Enrollment Status: Open: HCC, Straub, Pali Momi, QMC Cancer Type: Hematologic ClinicalTrials.gov ID: NCT04799275 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A151216 Local Principal Investigator: | Lung Keywords: Adjuvant Subtype: Adjuvant | Official Title: ALCHEMIST - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial Enrollment Status: Open: TCCOH, HCC, Hawaii Oncology, KMCWC, Straub, Pali Momi, Kuakini, QMC Cancer Type: Lung ClinicalTrials.gov ID: NCT02194738 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A081801 Local Principal Investigator: | Lung Keywords: Adjuvant Subtype: Adjuvant | Official Title: Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO Enrollment Status: Open: HCC, Straub, Pali Momi, QMC Cancer Type: Lung ClinicalTrials.gov ID: NCT04267848 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-LUNGMAP Local Principal Investigator: | Lung Keywords: Advanced/ Recurrent Subtype: Advanced/Metastatic 2nd line | Official Title: LUNGMAP: A Master Protocol to Evaluate Biomarker-driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study) Enrollment Status: Open: HCC, TCCOH, KMCWC, Straub, Pali Momi, QMC Cancer Type: Lung ClinicalTrials.gov ID: NCT03851445 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S1900E Local Principal Investigator: | Lung Keywords: Advanced/ Recurrent Subtype: Advanced/Metastatic 2nd line | Official Title: A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY) Enrollment Status: Open: HCC, Straub, Pali Momi, QMC Cohort 1 closed to accrual as of 12/13/2023 Cohort 2 will be closed to accrual as of 08/15/2024, Cohort 3 open Cancer Type: Lung ClinicalTrials.gov ID: NCT04625647 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S1900G Local Principal Investigator: | Lung Keywords: Advanced/ Recurrent Subtype: Advanced/Metastatic 2nd line | Official Title: A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) Enrollment Status: Open: HCC, QMC Opt out: HPH Cancer Type: Lung ClinicalTrials.gov ID: NCT05642572 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S2302 Local Principal Investigator: | Lung Keywords: Recurrent Subtype: Advanced/Metastatic 2nd line | Official Title: Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer Enrollment Status: Open: HCC, QMC, Straub, Pali Momi Cancer Type: Lung ClinicalTrials.gov ID: NCT05633602 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
NRG-LU008 Local Principal Investigator: | Lung Keywords: Advanced Subtype: Advanced/Metastatic 2nd line | Official Title: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer Enrollment Status: Open: HCC, QMC XRT: QMC Opt out: HPH Cancer Type: Lung ClinicalTrials.gov ID: NCT05624996 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S1827 Local Principal Investigator: | Lung Keywords: Post-adjuvant Subtype: Small Cell | Official Title: A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation (PCI) in Small-Cell Lung Cancer Enrollment Status: Open: TCCOH, HCC, Kuakini, Straub, Pali Momi, QMC Cancer Type: Lung ClinicalTrials.gov ID: NCT04155034 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
URCC-18110CD Local Principal Investigator: | Other Keywords: Educate, Nurture, Advise, Before Life Ends (ENABLE) Subtype: Supportive Care | Official Title: Implementing Palliative Care: Learning Collaborative vs. Technical Assistance Enrollment Status: Open: QMC Cancer Type: Other ClinicalTrials.gov ID: NCT04062552 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
FUKUI-2022-1 Local Principal Investigator: | Other Keywords: Parent-Child, Survivorship Subtype: Supportive Care | Official Title: Enhancing Connections-Palliative Care: A Cancer Parenting Program for Patients With Advanced Cancer and Their Children Enrollment Status: All sites may refer Cancer Type: Other ClinicalTrials.gov ID: NCT05477784 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
URCC-19075 Local Principal Investigator: | Other Keywords: Chemotherapy-Induced Peripheral Neuropathy Subtype: Supportive Care | Official Title: Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN) Enrollment Status: Open: HCC, KMCWC, Straub, Pali Momi Opt out: QMC Cancer Type: Other ClinicalTrials.gov ID: NCT04888988 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S2205 Local Principal Investigator: | Other Keywords: Prevention, Chemotherapy-Induced Peripheral Neuropathy Subtype: Supportive Care | Official Title: Ice Compress: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy Enrollment Status: Open: KMCWC only Cancer Type: Other ClinicalTrials.gov ID: NCT05642611 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ALLIANCE-A222004 Local Principal Investigator: | Other Keywords: Anorexia Subtype: Supportive Care | Official Title: A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia Enrollment Status: Open: HCC, KMCWC, Straub, Pali Pending: QMC Cancer Type: Other ClinicalTrials.gov ID: NCT04939090 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
URCC-18007 Local Principal Investigator: | Other Keywords: Fatigue Subtype: Symptom Management | Official Title: Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue Enrollment Status: Open: HCC, KMCWC, QMC Cancer Type: Other ClinicalTrials.gov ID: NCT03996265 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
URCC-19185 Local Principal Investigator: | Other Keywords: Insomnia Subtype: Symptom Management | Official Title: Multicenter Randomized Controlled Trial Comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL) Enrollment Status: Open: HCC, KMCWC, Straub, Pali Momi, TCCOH Opt out: QMC Cancer Type: Other ClinicalTrials.gov ID: NCT04829539 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
WF-1901 Local Principal Investigator: | Other Keywords: Pain Subtype: Symptom Management | Official Title: Internet-delivered Management of Pain Among Cancer Treatment Survivors Enrollment Status: Open: HCC, KMCWC, Straub, Pali Momi, QMC, FHP (Guam), TCCOH Cancer Type: Other ClinicalTrials.gov ID: NCT04462302 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
OKADO-2023-1 Local Principal Investigator: | Other Keywords: Breast Cancer, Rural Time to Treatment Initiation Subtype: Survey | Official Title: Improving time to treatment initiation for breast cancer patients in rural Hawaii Enrollment Status: All sites may refer Cancer Type: Other ClinicalTrials.gov ID: N/A Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
URCC-19178 Local Principal Investigator: | Other Keywords: Geriatric Survivorship health education Subtype: Geriatrics | Official Title: Optimizing Functional Outcomes of Older Cancer Survivors after Chemotherapy The GEM-S Study Enrollment Status: Open: KMCWC, Straub, Pali Momi Opt out: QMC Cancer Type: Other ClinicalTrials.gov ID: NCT05006482 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S1912CD (CREDIT) Local Principal Investigator: | Other Keywords: Metastatic / CCDR Subtype: Financial Toxicity | Official Title: A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT) Enrollment Status: Open: HCC, KMCWC, Pali Momi, Straub, QMC, FHP (Guam) Cancer Type: Other ClinicalTrials.gov ID: NCT04960787 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S2013 Local Principal Investigator: | Other Keywords: Immune Checkpoint Inhibitor Toxicity Subtype: Immune Checkpoint Inhibitor Toxicity | Official Title: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study Enrollment Status: Temporarily Closed to Accrual as of 05/06/2024 Cancer Type: Other ClinicalTrials.gov ID: NCT04871542 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
SWOG-S2108CD Local Principal Investigator: | Other Keywords: Genomic Tumor Board Subtype: Genomic Tumor Board | Official Title: A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) in Intervention to Usual Practice to Increase Evidence-based Genome-informed Therapy Enrollment Status: Open: HCC, KMCWC, Straub, Pali Momi, QMC Cancer Type: Other ClinicalTrials.gov ID: NCT05455606 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
ECOG-ACRIN-EAY191 Local Principal Investigator: | Other Keywords: ComboMATCH Subtype: Multiple Sites | Official Title: Molecular Analysis for Combination Therapy Choice (ComboMATCH) Enrollment Status: Open: HCC, KMCWC, Straub, Pali Momi, QMC Cancer Type: Other ClinicalTrials.gov ID: NCT05564377 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
DCP-001 Local Principal Investigator: | Other Keywords: Screening Subtype: Division of Cancer Prevention Studies | Official Title: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) Enrollment Status: Open: HCC, TCCOH, Castle, KMCWC, Straub, Pali Momi, QMC, TAMC, FHP (Guam) Cancer Type: Other ClinicalTrials.gov ID: N/A Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
DCP-002 Local Principal Investigator: | Other Keywords: Early onset malignancy Subtype: Division of Cancer Prevention Studies | Official Title: Early Onset Malignancies Initiative (EOMI): Molecular Profiling of Breast, Colorectal, Kidney, Liver, Prostate, and Multiple Myeloma among Racially and Ethnically Diverse Populations Enrollment Status: Temporarily Closed to Accrual as of 03/01/2024 Cancer Type: Other ClinicalTrials.gov ID: NCT04955808 Visit ClinicalTrials.gov for Complete Trial Details and Eligibility Requirements |
